Form 4: Sage Therapeutics Director's Stock Options Converted Following Supernus Merger Completion

Sage Therapeutics Director Geno J Germano's stock options were converted into cash and contingent value rights following the completion of the merger with Supernus Pharmaceuticals, Inc.

Summary

• Reporting Person Geno J Germano, a Director of Sage Therapeutics, Inc., disposed of 21,500 stock options due to the company's merger.
• The merger, effective July 31, 2025, involved Supernus Pharmaceuticals, Inc. acquiring Sage Therapeutics, Inc.
• Shareholders received $8.50 per share in cash plus one contingent value right (CVR) per share.
• Each CVR offers the potential to receive up to an additional $3.50 per share upon the satisfaction of specified milestones.
• Stock options with an exercise price less than the $8.50 closing amount, such as Germano's options with a $6.77 exercise price, were fully vested, cancelled, and converted into a cash payment (the difference between $8.50 and the exercise price, multiplied by the number of shares) plus one CVR per underlying share.
• Stock options with an exercise price greater than or equal to $8.50 were cancelled without consideration.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a merger, providing a defined cash value and potential upside via CVRs for shareholders and in-the-money option holders, which is generally positive for those stakeholders. However, options with higher exercise prices were cancelled without value, and the company ceases independent operation.

Positives

• Shareholders and in-the-money option holders received a cash payment of $8.50 per share.
• An additional potential future payout of up to $3.50 per share is available through Contingent Value Rights (CVRs) upon milestone achievement.
• In-the-money stock options were converted into cash and CVRs, providing value to option holders.

Negatives

• Stock options with an exercise price equal to or greater than the $8.50 closing amount were cancelled without any consideration.
• Sage Therapeutics, Inc. will no longer operate as an independent publicly traded entity following the merger.

Risks

• The value of the Contingent Value Rights (CVRs) is not guaranteed and is contingent upon the satisfaction of specified future milestones.

Future Outlook

The future outlook for Sage Therapeutics as an independent entity is concluded due to the merger. The remaining future financial potential for former shareholders and in-the-money option holders is tied to the achievement of milestones for the Contingent Value Rights (CVRs).

Industry Context

This transaction represents a consolidation event within the pharmaceutical or biotechnology sector, where larger companies acquire smaller ones, often for their pipeline assets or market position. Such mergers are common strategies for growth and portfolio expansion.

Comparison to Industry Standards

• The merger structure, including a cash component and a Contingent Value Right (CVR), is a common mechanism in pharmaceutical and biotechnology acquisitions, particularly when there is uncertainty around the future value of pipeline assets.
• Similar CVR structures have been used in acquisitions like Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of MyoKardia, where a portion of the deal value is tied to regulatory approvals or sales milestones of specific drugs.
• The $8.50 cash per share plus up to $3.50 CVR structure provides immediate liquidity while allowing for upside participation if specific drug development or commercialization goals are met, aligning with typical risk-sharing approaches in biotech M&A.

Stakeholder Impact

• Shareholders: Received $8.50 per share in cash and one Contingent Value Right (CVR) per share, providing immediate value and potential future upside.
• Option Holders: Those with in-the-money options received cash and CVRs, while those with out-of-the-money options had them cancelled without value.
• Employees: Employees who held stock options are impacted by the conversion or cancellation of their options.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to determine potential future payouts.

Key Dates

Keywords

Sage Therapeutics, SAGE, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Contingent Value Rights, CVR, Corporate Action